Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine and Rituximab in Post-transplant Lymphoproliferative Disorder (PLUTO)
NCT07573436Phase 2Not yet recruiting
- Sponsor
- University of Utah
- Start
- Nov 2026
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by University of Utah. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT07573436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573436.